KCT0008774尚未招募Unknown
A randomized, phase 2 trial of lazertinib and chemotherapy combination in EGFR-mutant NSCLC patients without ctDNA clearance after lead-in lazertinib monotherapy (CHAMELEON)
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 129
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Patients with histologically confirmed recurrent or metastatic non-squamous NSCLC without previous treatment experience
- •2.Presence of the sensitising EGFR-mutation (exon 19 deletion and/or L858R) detected by an accredited laboratory.
- •3.Measurable disease as defined according to RECIST v1.1
- •4.Age =19 years
- •5.ECOG performance status 0-2
- •6.Life expectancy =12 months
- •7.Adequate haematological function:
- •a.Haemoglobin =90 g/L
- •b.Absolute neutrophil count (ANC) = 1.5× 109/L
- •c.Platelet count =100× 109/L
- •8.Adequate renal function:
- •a.Serum creatinine =1.5x ULN or creatinine clearance =50 mL/min (calculated according to Cockcroft-Gault formula, see below).
- •b.Confirmation of creating clearance is only required when serum creatinine is >1.5x ULN.
- •Cockcroft-Gault formula:mL /min = (140-age [years ])×actual body weight [kg ]/(72× ?Creatinine ?_serum (mg /dL ) ) (×0.85 if female)
- •9.Adequate liver function:
- •a.ALT and AST =2.5× ULN. If the patient has liver metastases, ALT and AST must be =5× ULN
- •b.Total serum bilirubin =1.5× ULN. If the patient has documented Gilbert’s syndrome (unconjugated hyperbilirubinaemia) =3× ULN.
- •10.Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 7 days before enrolment.
- •11.Written IC for protocol treatment must be signed and dated by the patient and the investigator prior to any trial-related intervention.
排除标准
- •1.Presence of leptomeningeal metastases
- •2.Symptomatic spinal cord compression
- •3.Currently receiving (or unable to stop use prior to receiving the first dose of lazertinib treatment) medications or herbal supplements known to be potent CYP3A4 inducers that cannot be stopped before enrolment and for the duration of the trial.
- •4.Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.
- •5.Patients with a resolved or chronic HBV infection are eligible if they are:
- •a.Negative for HBsAg and positive for hepatitis B core antibody [anti-HBc IgG]; or
- •b.Positive for HBsAg, negative for HBeAg but for >6 months have had transaminases levels below ULN and HBV DNA levels below 2000 IU/mL (i.e., are in an inactive carrier state).
- •6.Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of lazertinib
- •7.Any of the following cardiac criteria:
- •a.QTcF >470 msec obtained from 3 ECGs, using the screening clinic ECG machine derived QTc value (QTcF: corrected QT interval using Fridericia's formula).
- •b.Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block or second-degree heart block).
- •c.Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP).
- •8.Past medical history of ILD, drug induced ILD, interstitial pneumonitis which required steroid treatment, or any evidence of clinically active ILD
- •9.History of hypersensitivity to active or inactive excipients of lazertinib or drugs with a similar chemical structure or class to lazertinib.
- •10.Patients who should not participate in the trial at the investigator’s discretion as they are unlikely to comply with trial procedures, restrictions, and requirements for pregnant or lactation women.
- •11.Both sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method (Please refer to 8.3 for highly effective contraceptive methods) during the trial and up to 6 months after discontinuing lazertinib treatment.
研究者
相似试验
招募中
不适用
A Study of Lazertinib as Consolidation Therapy in Patients with Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) following Chemoradiation TherapyKCT0007226Koera University Guro Hospital77
招募中
Unknown
A randomized study of LAZErtiNib alone versus Lazertinib plus bevaCizumab for Advanced non-small cell lung cancer with epidermal growth factor receptor activating mutations and smoking historyKCT0008295ational Cancer Center120
尚未招募
不适用
Phase II Trial of Lazertinib and Pemetrexed/Carboplatin Combination in Patients with Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Metastatic Non-Small Cell Lung Cancer with Asymptomatic or Mild Symptomatic Brain Metastases After Failure of OsimertinibKCT0007109The Catholic University of Korea, Seoul St. Mary's Hospital28
尚未招募
不适用
Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients with EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to prior lazertinib (LUCAS)NeoplasmsKCT0008198Yonsei University Health System, Severance Hospital87
进行中（未招募）
2 期
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung CancerNon-small Cell Lung CancerNCT06268210Yonsei University160